BioCryst Pharmaceutical Inc. (BCRX)

HEALTH CARE: PHARMACEUTICALS
SIC: BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)

4505 EMPEROR BOULEVARD DURHAM, NC 27703

BioCryst Pharmaceutical Inc. operates as a biopharmaceutical company which uses structure-based drug design to discover and design novel, small-molecule pharmaceutical products for the treatment of cancer, cardiovascular and autoimmune diseases and viral infections.

Data as of 2020-11-14
Market Cap778.654 Million Shares Outstanding176.566 Million Avg 30-day Volume4.438 Million
P/E Ratio Dividend Yield EPS-0.72
Price/Sales14.549 Price cash flow ratio Price free cash flow ratio-7.3
Book Value0.19 Price to Tangible Book22.31 Alpha-0.01
Short Interest Ratio % Short Interest to Float R-squared0.254223
BETA2.89294 52-week High/Low6.2862 / 1.58 Stddev0.241787
View SEC Filings from BCRX instead.
Q3 2020 All 13F Filers Prior Change Hedge Funds 1 Prior Change
In top 10: 2 3 -33.33% 2 (0.13%) 3 (0.19%) -33.33%
Funds Holding: 150 162 -7.41% 45 (2.96%) 55 (3.57%) -18.18%
13F shares: 126.472 Million 132.619 Million -4.63% 60.213 Million 67.625 Million -10.96%
% Ownership 71.6291 75.1685 -4.71% 34.1022 38.3297 -11.03%
New Positions: 24 48 -50.0% 5 20 -75.0%
Increased Positions 60 55 9.09% 15 15 0.0%
Closed Positions 31 21 47.62% 15 12 25.0%
Reduced Positions 43 37 16.22% 18 16 12.5%
Total Calls 1.293 Million 2.406 Million -46.25% 313.4 Thousand 976.7 Thousand -67.91%
Total Puts 1.293 Million 706.221 Thousand 83.08% 382.9 Thousand 220.5 Thousand 73.65%
PUT/CALL Ratio 1.0 0.29 244.83% 1.22 0.23 430.43%
1 hedge funds and active managers as identified by whalewisdom.com through public filings.

View recent insider trading info

Funds Holding BCRX (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding BCRX BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

none

Exercise Derivative Conversion (M)

none

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

HUTSON NANCY J

  • Director
63,315 2020-08-31 5

INGRAM ROBERT ALEXANDER

  • Director
69,605 2020-08-31 5

HEGGIE THERESA

  • Director
12,408 2020-08-31 5

ASELAGE STEVE

  • Director
28,613 2020-08-31 5

DOYLE ANTHONY CHIEF FINANCIAL OFFICER

  • Officer
54,000 2020-08-11 3

STONEHOUSE JON P PRESIDENT & CEO

  • Officer
  • Director
0 2020-05-13 4

ABERCROMBIE GEORGE B

  • Director
0 2020-05-12 1

LEE KENNETH B JR

  • Director
0 2020-05-12 1

THACKRAY HELEN M.

  • Director
0 2020-05-12 1

LEVIN ALAN G

  • Director
0 2020-05-12 3

STAAB THOMAS R II SENIOR VICE PRESIDENT AND CFO

  • Officer
0 2020-02-21 4

BABU YARLAGADDA S SENIOR VP - DRUG DISCOVERY

  • Officer
0 2020-02-21 3

SHERIDAN WILLIAM P SENIOR VP - CMO

  • Officer
0 2020-02-21 3

BARNES ALANE P SENIOR VP, CHIEF LEGAL OFFICER

  • Officer
0 2020-02-21 3

JONES MICHAEL L EXEC. DIRECTOR, FINANCE - PAO

  • Officer
0 2020-02-21 3

GAYER CHARLES K VICE PRESIDENT AND CCO

  • Officer
127,315 2020-01-15 1

SNIECINSKI MEGAN CHIEF BUSINESS OFFICER

  • Officer
0 2019-12-17 2

POWELL LYNNE SENIOR VP - CCO

  • Officer
0 2019-01-25 0

ERCK STANLEY C

  • Director
48,333 2018-11-28 0

COHEN FRED E

  • Director
0 2018-06-20 0

PATEL SANJ K

  • Director
0 2017-05-24 0

BAKER BROS. ADVISORS LP

BAKER BROS. ADVISORS (GP) LLC

BAKER JULIAN

BAKER FELIX

  • 10% Owner
11,016,695 2016-08-12 0

SANDERS CHARLES A

  • Director
12,971 2016-02-29 0

JENSEN PEDER

  • Director
0 2014-05-02 0

BAKER FELIX

BAKER BROS. INVESTMENTS II, L.P.

BAKER/TISCH INVESTMENTS, LP

667, L.P.

BAKER BROTHERS LIFE SCIENCES LP

14159, L.P.

BAKER BROS. ADVISORS LP

BAKER JULIAN

BAKER BROS. ADVISORS (GP) LLC

BAKER BROS. INVESTMENTS, L.P.

  • 10% Owner
6,699,979 2013-08-01 0

BAKER BROS. ADVISORS (GP) LLC

  • 10% Owner
0 2013-07-01 0

HOROVITZ ZOLA P

  • Director
0 2012-05-23 0

HIGGINS JOHN L

  • Director
0 2012-05-23 0

BAKER BROS ADVISORS LLC

  • 10% Owner
0 2012-04-12 0

MCCULLOUGH DAVID VP

  • Officer
24,124 2012-03-15 0

LOWREY ROBERT S CONTROLLER, PAO

  • Officer
9,766 2012-03-15 0

BAKER BROTHERS LIFE SCIENCES CAPITAL (GP), LLC

BAKER JULIAN

BAKER FELIX

  • 10% Owner
3,841,124 2011-06-30 0

BAKER BROS. CAPITAL (GP), LLC

BAKER JULIAN

BAKER FELIX

  • 10% Owner
62,407 2011-06-30 0

BIGGAR STEPHEN R

  • Director
0 2011-05-12 0

GRANT STUART SR VP & CFO

  • Officer
57,102 2011-03-16 0

SEIDENBERG BETH C

  • Director
0 2010-05-13 0

FEATHERINGILL WILLIAM W

  • Director
  • 10% Owner
0 2010-05-13 0

MILLS MIKE PRINCIPAL ACCOUNTING OFFICER

  • Officer
0 2010-03-12 0

BAKER / TISCH CAPITAL (GP), LLC

BAKER JULIAN

BAKER FELIX

  • 10% Owner
17,241 2009-05-28 0

14159 CAPITAL (GP), LLC

BAKER JULIAN

BAKER FELIX

  • 10% Owner
120,828 2009-05-28 0

BAKER BIOTECH CAPITAL (GP), LLC

BAKER JULIAN

BAKER FELIX

  • 10% Owner
1,522,015 2009-05-28 0

DARWIN MICHAEL A PRINCIPAL ACCOUNTING OFFICER

  • Officer
3,048 2008-07-31 0

STEER RANDOLPH C

  • Director
0 2008-05-21 0

BENNETT J CLAUDE CHIEF OPERATING OFFICER

  • Officer
  • Director
0 2008-03-14 0

Insider Transactions Last 60 Days

Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
Disposed
Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days
No current insider transactions

* -

Transaction Code Definitions
Code Definition
A Grant, award or other acquisition pursuant to Rule 16b-3(d)
C Conversion of derivative security
D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
E Expiration of short derivative position
F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
G Bona fide gift
H Expiration (or cancellation) of long derivative position with value received
I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
J Other acquisition or disposition
L Small acquisition under Rule 16a-6
M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
O Exercise of out-of-the-money derivative security
P Open market or private purchase of non-derivative or derivative security
S Open market or private sale of non-derivative or derivative security
U Disposition pursuant to a tender of shares in a change of control transaction
W Acquisition or disposition by will or the laws of descent and distribution
X Exercise of in-the-money or at-the-money derivative security
Z Deposit into or withdrawal from voting trust

Elevate your investments